Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the capacity of the Accelerated Access Pathway to consider treatments for rare diseases, including muscle-wasting conditions, to be considered for fast-track breakthrough designation.

The Accelerated Access Collaborative (AAC) will define the criteria for breakthrough products in the coming months. As set out in the response to the Accelerated Access Response, the AAC will focus on affordable products which can dramatically improve efficiency, fill an unmet need or make a step change in patient outcomes.